Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (LCTX) announced it will report its Q2 2022 financial results on August 11, 2022, after market close. A conference call will follow at 4:30 p.m. ET. Participants can access the call by dialing (800) 715-9871 in the U.S. and (646) 307-1952 internationally. Lineage specializes in developing allogeneic cell therapies for unmet medical needs, with its pipeline including five candidates targeting conditions like age-related macular degeneration and acute spinal cord injuries.
Lineage Cell Therapeutics has expanded its collaboration with Advanced BioMatrix to include clinical-grade HyStem technology supply for cell therapies. The amended agreement increases milestone payments and royalties for Lineage, enhancing potential revenue streams. CEO Brian M. Culley emphasized a focus on business development and monetizing their technology platform. HyStem, a patented hydrogel, supports various cell types and is crucial for cell functionality. With clinical programs targeting significant market opportunities, this partnership positions Lineage for improved cash flow and supports its development pipeline.
Lineage Cell Therapeutics (LCTX) reported strong financial results for Q1 2022, with revenues increasing to $5.2 million from $0.4 million YoY, attributable to a $50 million licensing payment from Roche. Operating expenses rose to $11.5 million, driven by a $3.5 million one-time expense related to litigation. The company completed patient enrollment for the VAC2 Phase 1 study and showcased promising clinical results for OpRegen in addressing geographic atrophy from AMD. As of March 31, 2022, cash reserves stood at $78.1 million, supporting ongoing clinical and regulatory efforts.
Lineage Cell Therapeutics (LCTX) will report its Q1 2022 financial and operational results on May 12, 2022, post-market closure. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and provide a business update. The call can be accessed via a designated phone line, and a live webcast will be available on their investor website, with replays offered for 30 days. Lineage specializes in developing allogeneic cell therapies, focusing on addressing significant medical needs through innovative cell-based interventions.
Lineage Cell Therapeutics (LCTX) presented data from its Phase 1/2a study of OpRegen, a cell therapy for geographic atrophy (GA) due to age-related macular degeneration (AMD), at the 2022 ARVO Annual Meeting. The 12-month primary endpoint data indicate OpRegen is well-tolerated, showing an acceptable safety profile. Preliminary improvements in visual function were noted in Cohort 4 patients with GA, with an average 7.6 letter gain in visual acuity. These findings support further development of OpRegen as a potential treatment for GA, previously thought to have no effective interventions.
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) announced a fireside chat with CEO Brian M. Culley scheduled for April 27, 2022, at 3:30 PM EST. The event will be hosted by Mayank Mamtani, Senior Analyst at B. Riley Securities, focusing on two new cell therapy programs stemming from the collaboration with Roche and Genentech for the RG6501 (OpRegen®) program.
Lineage specializes in developing allogeneic cell therapies, targeting unmet medical needs in significant markets.
Lineage Cell Therapeutics (LCTX) announced a new development program for photoreceptor neural cell (PNC) transplants aimed at treating vision loss due to photoreceptor dysfunction. The company has filed for intellectual property protection regarding PNC manufacturing methods and demonstrated feasibility for large-scale production of photoreceptors. This initiative comes following a significant alliance with Roche and Genentech worth up to $670 million. Lineage aims to leverage its technology platform for clinical and commercial advancements in cell therapies.
Lineage Cell Therapeutics (LCTX) announced that Cancer Research UK has completed patient enrollment in the Phase 1 clinical trial for VAC2, an allogeneic cancer vaccine designed for non-small cell lung cancer (NSCLC). Lineage has now taken over responsibility for further clinical development of VAC2. Initial clinical results are expected later this year. Lineage's manufacturing improvements aim to prepare VAC2 for future trials, including an Investigational New Drug Application submission to the FDA. This step underlines their commitment to advancing innovative cancer therapies.
Lineage Cell Therapeutics, a clinical-stage biotech company, announced CEO Brian M. Culley will present at NobleCon18, on April 20, 2022, at 4:30 PM ET. The conference will be held at the Hard Rock Hotel & Casino in Hollywood, Florida, from April 19-21. Lineage specializes in allogeneic cell therapies aimed at significant medical needs, with products like OpRegen for macular degeneration and OPC1 for spinal cord injuries. An archived webcast of the presentation will be available from April 21 on the Lineage website.
Lineage Cell Therapeutics, Inc. (LCTX) will present at the 2022 Virtual Growth Conference on March 28, 2022, at 10 AM ET. CEO Brian M. Culley will participate in an Ophthalmology Panel and provide a corporate overview available on demand from the same date. The event, hosted by Maxim Group LLC and M-Vest, requires registration for participation. Lineage focuses on developing allogeneic cell therapies for unmet needs, including therapies for dry age-related macular degeneration and acute spinal cord injuries, with substantial market opportunities.